Published in J Transl Med on December 14, 2011
Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions. Genome Biol (2015) 0.88
A cell cycle role for the epigenetic factor CTCF-L/BORIS. PLoS One (2012) 0.87
Clinico-pathologic relevance of Survivin splice variant expression in cancer. Cancer Lett (2013) 0.84
BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer. Cancer Immun (2013) 0.81
High expression of hTERT and stemness genes in BORIS/CTCFL positive cells isolated from embryonic cancer cells. PLoS One (2014) 0.79
Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells. Neoplasia (2012) 0.79
CTCFL (BORIS) mRNA Expression in a Peripheral Giant Cell Granuloma of the Oral Cavity. Case Rep Dent (2014) 0.75
Expression of the brother of the regulator of imprinted sites gene in the sputum of patients with lung cancer. Korean J Thorac Cardiovasc Surg (2014) 0.75
CTCF: master weaver of the genome. Cell (2009) 15.09
Genome-wide identification of in vivo protein-DNA binding sites from ChIP-Seq data. Nucleic Acids Res (2008) 8.89
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet (2001) 6.80
Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are tethered together selectively by the cell-proliferation factor HCF-1. Genes Dev (2003) 4.73
An epigenetic road map for histone lysine methylation. J Cell Sci (2003) 4.43
Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature (2007) 3.68
High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol (2010) 3.21
Repressive and active histone methylation mark distinct promoters in human and mouse spermatozoa. Nat Struct Mol Biol (2010) 3.07
CTCF-dependent chromatin insulator is linked to epigenetic remodeling. Mol Cell (2006) 2.93
The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol (2002) 2.66
BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A (2002) 2.62
The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation. PLoS Biol (2006) 2.43
The pluripotency factor Oct4 interacts with Ctcf and also controls X-chromosome pairing and counting. Nature (2009) 2.40
Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell (2009) 2.21
Early origins of modern birds and mammals: molecules vs. morphology. Bioessays (1999) 2.09
Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res (2005) 2.08
Does CTCF mediate between nuclear organization and gene expression? Bioessays (2010) 2.02
BRCA1 functions as a breast stem cell regulator. J Med Genet (2004) 1.92
Transcriptional repression by the insulator protein CTCF involves histone deacetylases. Nucleic Acids Res (2000) 1.74
Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res (2005) 1.74
CTCF cis-regulates trinucleotide repeat instability in an epigenetic manner: a novel basis for mutational hot spot determination. PLoS Genet (2008) 1.72
PRMT7 is a member of the protein arginine methyltransferase family with a distinct substrate specificity. J Biol Chem (2004) 1.63
Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore) (1998) 1.55
Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet (2003) 1.54
DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun (2007) 1.53
Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One (2009) 1.45
Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res (2011) 1.38
Cancer/testis antigens and gametogenesis: a review and "brain-storming" session. Cancer Cell Int (2005) 1.30
Molecular evolutionary genomics of birds. Cytogenet Genome Res (2007) 1.29
BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression. Mol Cell Biol (2008) 1.26
Physical and functional interaction between two pluripotent proteins, the Y-box DNA/RNA-binding factor, YB-1, and the multivalent zinc finger factor, CTCF. J Biol Chem (2000) 1.26
Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res (2007) 1.23
BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer (2008) 1.20
Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int J Cancer (2008) 1.18
DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylation. Cancer Res (2008) 1.17
Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines. Oncogene (2010) 1.16
Epigenetic regulation in mammalian preimplantation embryo development. Reprod Biol Endocrinol (2009) 1.15
The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes. PLoS Genet (2008) 1.14
Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol (2006) 1.13
Differential expression of the embryo/cancer gene ECSA(DPPA2), the cancer/testis gene BORIS and the pluripotency structural gene OCT4, in human preimplantation development. Mol Hum Reprod (2008) 1.08
Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast. Genes Chromosomes Cancer (2006) 1.07
Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem (2006) 1.07
CTCF regulates the local epigenetic state of ribosomal DNA repeats. Epigenetics Chromatin (2010) 1.06
BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells. Nucleic Acids Res (2010) 1.04
Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene (2007) 1.03
Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun (2008) 1.03
Evolutionary diversification of SPANX-N sperm protein gene structure and expression. PLoS One (2007) 1.02
The structural complexity of the human BORIS gene in gametogenesis and cancer. PLoS One (2010) 1.02
CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region. Cancer Res (2008) 0.99
Expression of a testis-specific form of Gal3st1 (CST), a gene essential for spermatogenesis, is regulated by the CTCF paralogous gene BORIS. Mol Cell Biol (2010) 0.96
Expression analysis of candidate breast tumour suppressor genes on chromosome 16q. Breast Cancer Res (2005) 0.96
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93
Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cell Immunol (2011) 0.91
DNA methylation dysregulates and silences the HLA-DQ locus by altering chromatin architecture. Genes Immun (2011) 0.91
DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Ther (2007) 0.89
Modulation of thyroid hormone receptor silencing function by co-repressors and a synergizing transcription factor. Biochem Soc Trans (2000) 0.89
BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas. PLoS One (2010) 0.88
BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines. Cancer Immun (2010) 0.87
Molecular architecture of CTCFL. Biochem Biophys Res Commun (2010) 0.83
Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosomes Cancer (2005) 0.82
Susceptibility for breast cancer in young patients with short rare minisatellite alleles of BORIS. BMB Rep (2010) 0.79
Differences in evolutionary pressure acting within highly conserved ortholog groups. BMC Evol Biol (2008) 0.78
AP endonuclease-independent DNA base excision repair in human cells. Mol Cell (2004) 3.37
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol (2008) 2.38
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood (2009) 2.14
The molecular architecture of the mammalian DNA repair enzyme, polynucleotide kinase. Mol Cell (2005) 2.09
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol (2003) 2.02
Involvement of human polynucleotide kinase in double-strand break repair by non-homologous end joining. EMBO J (2002) 1.93
Differentiated keratinocyte-releasable stratifin (14-3-3 sigma) stimulates MMP-1 expression in dermal fibroblasts. J Invest Dermatol (2005) 1.88
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood (2008) 1.74
Systemic lupus erythematosus associated with paclitaxel use in the treatment of ovarian cancer. South Med J (2008) 1.58
Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol (2005) 1.56
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol (2009) 1.46
NEIL2-initiated, APE-independent repair of oxidized bases in DNA: Evidence for a repair complex in human cells. DNA Repair (Amst) (2006) 1.45
Polycystic ovary syndrome: focus on platelets and prothrombotic risk. South Med J (2011) 1.44
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
H. pylori-associated gastric cancer in a husband-wife pair: a veritable family affair. South Med J (2009) 1.38
The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One (2011) 1.37
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci (2007) 1.31
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30
Stable down-regulation of human polynucleotide kinase enhances spontaneous mutation frequency and sensitizes cells to genotoxic agents. Proc Natl Acad Sci U S A (2004) 1.27
Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia? J Transl Med (2008) 1.27
Pathways of proliferation and antiapoptosis driven in breast cancer stem cells by stem cell protein piwil2. Cancer Res (2010) 1.26
Exosome removal as a therapeutic adjuvant in cancer. J Transl Med (2012) 1.24
Behavioral factors of patients before and after diagnosis with melanoma: a cohort study - are sun-protection measures being implemented? Melanoma Res (2010) 1.22
Pnk1, a DNA kinase/phosphatase required for normal response to DNA damage by gamma-radiation or camptothecin in Schizosaccharomyces pombe. J Biol Chem (2001) 1.20
Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol (2010) 1.19
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant (2003) 1.18
A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci (2013) 1.17
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
Keratinocyte-releasable stratifin functions as a potent collagenase-stimulating factor in fibroblasts. J Invest Dermatol (2004) 1.10
Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma. Dermatol Online J (2006) 1.09
Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice. Neurosci Lett (2003) 1.09
Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine (2005) 1.09
Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem (2006) 1.07
XRCC1 stimulates polynucleotide kinase by enhancing its damage discrimination and displacement from DNA repair intermediates. J Biol Chem (2007) 1.06
Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett (2004) 1.05
Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia. MedGenMed (2007) 1.04
A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood (2009) 1.04
Multiple myeloma bone marrow niche. Curr Pharm Biotechnol (2009) 1.04
Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun (2008) 1.03
Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol (2010) 1.03
Biophysical characterization of human XRCC1 and its binding to damaged and undamaged DNA. Biochemistry (2004) 1.03
Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci (2013) 1.02
Tumor vaccines in 2010: need for integration. Cell Immunol (2010) 1.02
Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol (2008) 1.01
Practices, attitudes, and beliefs associated with complementary and alternative medicine (CAM) use among cancer patients. Integr Cancer Ther (2012) 0.99
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol (2009) 0.97
Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J Neuroinflammation (2008) 0.97
Mass spectrometric studies on epigenetic interaction networks in cell differentiation. J Biol Chem (2011) 0.96
PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PLoS One (2011) 0.96
Lasers, stem cells, and COPD. J Transl Med (2010) 0.95
Identification of a small molecule inhibitor of the human DNA repair enzyme polynucleotide kinase/phosphatase. Cancer Res (2009) 0.95
Independent mechanisms of stimulation of polynucleotide kinase/phosphatase by phosphorylated and non-phosphorylated XRCC1. Nucleic Acids Res (2009) 0.95
Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. Hum Vaccin Immunother (2013) 0.94
DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J Neuroimmunol (2008) 0.94
Immunological factors that affect the in vivo fate of T7 phage in the mouse. J Virol Methods (2004) 0.94
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93
Does bortezomib induce de facto varicella zoster virus reactivation in patients with multiple myeloma? J Clin Oncol (2009) 0.91
ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. J Hepatol (2008) 0.91
Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cell Immunol (2011) 0.91
Cleavage of misfolded nuclear receptor corepressor confers resistance to unfolded protein response-induced apoptosis. Cancer Res (2006) 0.90
Delivery of a DNA vaccine for Alzheimer's disease by electroporation versus gene gun generates potent and similar immune responses. Neurodegener Dis (2012) 0.90
Spectroscopic studies of DNA and ATP binding to human polynucleotide kinase: evidence for a ternary complex. Biochemistry (2003) 0.90
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br J Haematol (2011) 0.89
Tissue engineering, regenerative medicine, and rejuvenation in 2010: the role of adipose-derived stem cells. Facial Plast Surg (2011) 0.88
A case of prekallikrein deficiency resulting in severe recurrent mucosal hemorrhage. Am J Med Sci (2009) 0.88
Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. PLoS One (2011) 0.87
The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. J Transl Med (2011) 0.87
Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling. Exp Hematol (2007) 0.87
Thrombopoietin enhances generation of CD34+ cells from human embryonic stem cells. Stem Cells (2007) 0.87
Autologous stromal vascular fraction cells: a tool for facilitating tolerance in rheumatic disease. Cell Immunol (2010) 0.86
Malignant melanoma in African-Americans. Dermatol Online J (2009) 0.86
Dissecting DNA-protein and protein-protein interactions involved in bacterial transcriptional regulation by a sensitive protein array method combining a near-infrared fluorescence detection. Proteomics (2003) 0.86
Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I. CNS Neurol Disord Drug Targets (2009) 0.86
Inhibition of intracranial glioma growth by endometrial regenerative cells. Cell Cycle (2009) 0.85
Combination stem cell therapy for heart failure. Int Arch Med (2010) 0.85
Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J (2007) 0.85
Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy. J Transl Med (2011) 0.85
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther (2011) 0.85
Small cell lung cancer with paraneoplastic lipase production. South Med J (2010) 0.85
Clinico-pathologic relevance of Survivin splice variant expression in cancer. Cancer Lett (2013) 0.84